CURRENT MEDICAL DIAGNOSIS AND
TREATMENT 2026
65TH EDITION
Author(s)Maxine A. Papadakis; Michael
W. Rabow; Kenneth R. McQuaid; Paul L.
Nadler; Erika Leemann Price
TEST BANK
1)
Reference
Ch. 1 — Disease Prevention & Health Promotion —
Hypertension: confirmation & initial evaluation
,Stem
A 48-year-old man attends for a routine exam. Office blood
pressure readings at two visits over two weeks averaged 148/92
mm Hg. He has a BMI of 31 kg/m², no target-organ symptoms,
and an otherwise unremarkable exam. Which next step best
aligns with CMDT-recommended confirmation of new
hypertension before initiating long-term therapy?
A. Start ACE inhibitor therapy and recheck blood pressure in 4
weeks.
B. Obtain home blood pressure measurements or 24-hour
ambulatory blood pressure monitoring.
C. Order urgent renal ultrasound and plasma renin activity.
D. Advise lifestyle changes only and wait 6 months before
reassessment.
Correct answer: B
,Rationale — Correct (B)
CMDT emphasizes confirming elevated office pressures with
out-of-office measurement (home BP monitoring or 24-hour
ambulatory monitoring) to exclude white-coat hypertension
and to guide management. Ambulatory/home monitoring
provides more reliable estimates of true BP exposure before
committing to lifelong pharmacotherapy.
Rationale — Incorrect
A. Starting medication immediately risks treating white-coat
hypertension without objective out-of-office confirmation.
C. Renal imaging and renin testing are reserved for suspected
secondary hypertension or resistant cases, not initial
confirmation.
D. Waiting 6 months without objective confirmation delays
diagnosis and risk stratification; short-term lifestyle
modification plus out-of-office confirmation is preferred.
, Teaching point: Confirm elevated clinic BP with home or
ambulatory measurements before long-term therapy.
Citation (Simplified APA):
Papadakis, M. A., McPhee, S. J., & Rabow, M. W. (2026). Current
Medical Diagnosis & Treatment (65th ed.). Ch. 1.
2)
Reference
Ch. 1 — Disease Prevention & Health Promotion —
Cardiovascular risk assessment & statin primary prevention
Stem
A 54-year-old woman with treated hypertension and total
cholesterol 220 mg/dL presents for preventive care. She is a
non-smoker, physically inactive, BMI 29. Her 10-year ASCVD risk
estimate is 9%. She asks whether she should start a daily statin
TREATMENT 2026
65TH EDITION
Author(s)Maxine A. Papadakis; Michael
W. Rabow; Kenneth R. McQuaid; Paul L.
Nadler; Erika Leemann Price
TEST BANK
1)
Reference
Ch. 1 — Disease Prevention & Health Promotion —
Hypertension: confirmation & initial evaluation
,Stem
A 48-year-old man attends for a routine exam. Office blood
pressure readings at two visits over two weeks averaged 148/92
mm Hg. He has a BMI of 31 kg/m², no target-organ symptoms,
and an otherwise unremarkable exam. Which next step best
aligns with CMDT-recommended confirmation of new
hypertension before initiating long-term therapy?
A. Start ACE inhibitor therapy and recheck blood pressure in 4
weeks.
B. Obtain home blood pressure measurements or 24-hour
ambulatory blood pressure monitoring.
C. Order urgent renal ultrasound and plasma renin activity.
D. Advise lifestyle changes only and wait 6 months before
reassessment.
Correct answer: B
,Rationale — Correct (B)
CMDT emphasizes confirming elevated office pressures with
out-of-office measurement (home BP monitoring or 24-hour
ambulatory monitoring) to exclude white-coat hypertension
and to guide management. Ambulatory/home monitoring
provides more reliable estimates of true BP exposure before
committing to lifelong pharmacotherapy.
Rationale — Incorrect
A. Starting medication immediately risks treating white-coat
hypertension without objective out-of-office confirmation.
C. Renal imaging and renin testing are reserved for suspected
secondary hypertension or resistant cases, not initial
confirmation.
D. Waiting 6 months without objective confirmation delays
diagnosis and risk stratification; short-term lifestyle
modification plus out-of-office confirmation is preferred.
, Teaching point: Confirm elevated clinic BP with home or
ambulatory measurements before long-term therapy.
Citation (Simplified APA):
Papadakis, M. A., McPhee, S. J., & Rabow, M. W. (2026). Current
Medical Diagnosis & Treatment (65th ed.). Ch. 1.
2)
Reference
Ch. 1 — Disease Prevention & Health Promotion —
Cardiovascular risk assessment & statin primary prevention
Stem
A 54-year-old woman with treated hypertension and total
cholesterol 220 mg/dL presents for preventive care. She is a
non-smoker, physically inactive, BMI 29. Her 10-year ASCVD risk
estimate is 9%. She asks whether she should start a daily statin
